6th October, 2009 - Orexo AB today confirms that its partner, ProStrakan Group plc, has announced that the New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA).
The details can be read here.
No comments:
Post a Comment